The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
In this study it will be investigated if patients with atopic dermatitis responding to EPOGAM treatment, show a significant increase of dihomo-gamma-linolic acid in the blood.
Condition or disease
Drug: EPOGAM 1000
Patients with atopic dermatitis will receive EPOGAM 1000 for 12 weeks. Clinical symptoms of the disease will be assessed using the SCORAD score. Dihomo-gamma-linolic acid levels in the blood will be measured with GC-MS.
One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
2 Years to 45 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
atopic dermatitis since at least 2 months (criteria after Hanifin and Rajka, 1980)
men or women aged 2 - 45 years
women of childbearing age using contraception
informed consent of the patient or of the parents
abuse of drugs or alcohol
glaucoma, cataract or ocular herpes simplex
clinical relevant changes in laboratory parameters
scabies, infections with dermathophytae, HIV-associated dermatosis
patients enrolled in other studies
progredient, systemic diseases
pregnancy and lactation
severe internistic diseases
organ transplantation in the medical history
hypersensitivity against an ingredient of the study medication